Prostate Cancer (Adenocarcinoma)
Conditions
Keywords
HOOD technique, Prostate cancer, Nerve-sparing
Brief summary
This prospective, non-randomized cohort study included consecutive patients undergoing robotic-assisted laparoscopic radical prostatectomy (RARP) between January 2024 and January 2026 following ethics committee approval. Patients with clinically localized prostate cancer eligible for bilateral nerve-sparing surgery were enrolled. Two surgical techniques-anterior-posterior reconstruction (APR) and the HOOD technique-were compared. All procedures were performed by a single high-volume surgeon at a tertiary referral center. The primary endpoint was early urinary continence recovery, assessed at catheter removal and at 3, 6, and 12 weeks postoperatively. Secondary outcomes included postoperative complications, positive surgical margin rates, and early oncological outcomes.
Interventions
PROCEDUREProstatectomy with anterior-posterior renconstruciton
Prostatectomy with anterior-posterior reconstruction involves restoration of both the posterior musculofascial plate and the anterior periurethral support structures during vesicourethral anastomosis, aiming to re-establish normal pelvic anatomy and improve early postoperative urinary continence following radical prostatectomy.
PROCEDUREProstatectomy with HOOD techinque
Prostatectomy with the HOOD (Hood technique) is a nerve-sparing approach in which the anterior periprostatic structures, including the detrusor apron and puboprostatic ligaments, are preserved to maintain anterior urethral support and neurovascular integrity, with the aim of improving early urinary continence and functional recovery after radical prostatectomy.
Sponsors
Araz Musaev
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* life expectancy \>10 years, * clinically organ confined disease (cT1-cT2), * biopsy ISUP GG ≤3, * total serum prostate-specific antigen (PSA) ≤10 ng/ml * normal preoperative continence and potency
Exclusion criteria
* high risk prosatate cancer * cN1 * M1 prostate cancer (according to preoperative GA68 PSMA PET CT) * pre-existing urinary incontinence, * previous prostatic, urethral, bladder neck surgery * neoadjuvant therapy * prior pelvic radiotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional outcomes | 3 weeks , 6 weeks and 12 weeks after surgery. | The Urinary continance recovery rates at the catheter removal, and subsequently at 3 weeks , 6 weeks and 12 weeks after surgery. |
Countries
Turkey (Türkiye)
Outcome results
None listed